SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-057945
Filing Date
2022-02-28
Accepted
2022-02-28 16:23:21
Documents
17
Period of Report
2022-02-28
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d284805d8k.htm   iXBRL 8-K 36785
2 EX-99.1 d284805dex991.htm EX-99.1 41437
6 GRAPHIC g284805dsp2.jpg GRAPHIC 5262
7 GRAPHIC g284805g0228133632996.jpg GRAPHIC 2197
8 GRAPHIC g284805g0228133633621.jpg GRAPHIC 4912
9 GRAPHIC g284805g0228133634043.jpg GRAPHIC 2995
  Complete submission text file 0001193125-22-057945.txt   239216

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ntla-20220228.xsd EX-101.SCH 2853
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20220228_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20220228_pre.xml EX-101.PRE 11259
11 EXTRACTED XBRL INSTANCE DOCUMENT d284805d8k_htm.xml XML 3344
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 22690012
SIC: 2835 In Vitro & In Vivo Diagnostic Substances